Navigation Links
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
Date:6/4/2009

NEWPORT, Ky., June 4 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Michael J. Valentino has been named to the position of President and Chief Executive Officer and continues as a member of the Company's Board of Directors. In addition to Mr. Valentino's announcement, Xanodyne completed an equity financing of $38 million led by MPM Capital. Current investors' participation also included; AIG Investments' sponsored funds, Aisling Capital, Blue Chip Venture Company, Essex Woodlands Health Ventures, HealthCare Ventures, LLC, and Union Springs.

Mr. Valentino most recently served as President and CEO, Adams Respiratory Therapeutics (Nasdaq: ARXT) and has over 30 years of experience in the healthcare industry, including a broad range of critical leadership positions at major pharmaceutical companies including Alpharma, Novartis AG, Pharmacia/Upjohn and Warner Lambert. Mr. Valentino successfully transformed Adams into a fully integrated specialty pharmaceutical company. In addition, under his leadership Adams completed its initial public offering in July 2005, which was ranked by The Wall Street Journal as the No. 1 Health Care IPO in 2005. In January 2008, he successfully led the sale of the company to Reckitt Benckiser for $2.3B.

Mr. Valentino said, "I look forward to working closely with the Xanodyne management team to bring two exciting pipeline assets to the US marketplace within the next 12-18 months. Our efforts will be focused on aggressively executing our commercialization plans for Zipsor(TM) (diclofenac potassium - acute pain) and XP12B (tranexamic acid - heavy menstrual bleeding). The closing of our financing demonstrates the continued commitment of our investor group to complete the NDA process and execute the launch plans for these two important new products."


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Xanodynes New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
2. US Oncology, Inc. Announces $465 Million Senior Secured Notes Offering
3. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
4. CorVel Announces Revenues and Earnings
5. Conceptual Options, a Center for Surrogacy & Egg Donation, Announces Third Party Assurance Program
6. Orlando Dermatology Aesthetic & Clinical (ODAC) Conference Announces Its 2010 Event
7. Synthetech Announces Fiscal 2009 Results
8. Martek Announces Second Quarter 2009 Financial Results
9. Medi-Share Program Announces New Healthcare Program Offerings for Christian Community
10. Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis
11. One Woman Initiative Announces First Grants to Womens Organizations in Five Nations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014)A diet rich in soy may help feminine hearts, ... today in Menopause , the journal of The ... to the diet of women in Asia, produces the ... similar to Asian migrants to North America, leads to ... and switching to soy from a Western diet after ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates in ... method was created for any sufferer who is looking for ... The author of the new program, Sarah Summer, says that ... suffered from yeast infection, too. Actually, this is the reason ... this problem. , The Natural Cure for Yeast ...
(Date:7/29/2014)... Port Washington, New York (PRWEB) July 29, 2014 ... dedicated to protecting the rights of victims injured by ... action lawsuit has been filed by plaintiffs in Canada ... increased risk of cardiovascular events with the low ... was filed on July 22, 2014 in the Ontario ...
(Date:7/29/2014)... Regardless of the good things that ... to share those with. Love is about understanding, commitment ... Love is also about overcoming all the challenges that ... perfect relationship, women need to know how to understand ... Him program, please visit the official website at ...
(Date:7/29/2014)... of severe combat injuries threatening more than one limb, ... record of safety and effectiveness in avoiding amputation, reports ... Plastic and Reconstructive Surgery , the official medical ... (ASPS). , Experience with multiple limb salvage procedures ... success rates, with no increase in complications compared to ...
Breaking Medicine News(10 mins):Health News:Soy may help women's hearts if they start early 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2
... TALLAHASSEE, Fla., Aug. 12 With the recent increase in ... in these already hard economic times - do they pay the ... those who want to quit, The Florida Quitline (1-877-U-CAN-NOW) is here ... , , According to Kim Berfield, Deputy Secretary ...
... , , , , ... a leading provider of Linux-bas e d ... Systems, a national health care management company, has deployed Arkeia Network Backup. ... Goold has realized dramatic improvements in backup performance and in backup administration. ...
... Fountain Healthy Aging,Inc. announced on August 12 2009 that ... Oak Resources Limited which provides the Company,with a $5,000,000 Equity ... has the right to draw down from the Equity Line,Investment ... of 24 months. The,first tranche investment of $1,000,000 was drawn ...
... , WESTFIELD, Ind., Aug. 12 maxIT ... healthcare providers, announced the successful "Stage 6" designation of Gila ... in Silver City, New Mexico. maxIT assisted the Phoenix Health ... to support the implementation of several HIS modules. Beginning ...
... , , , ... (NYSE: HI ) -- Hillenbrand, Inc. reported net revenues of ... 2009, a $6.3 million (3.8 percent) decline from the same period in ... million (4.9 percent) decline. The difference in as-adjusted net income for the ...
... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
Cached Medicine News:Health News:The Time To Quit Is Now -- Free NRT Is Available 2Health News:Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup 2Health News:Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup 3Health News:Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured 2Health News:Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured 3Health News:maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 2Health News:maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 3Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 2Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 3Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 4Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 5Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 6Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 7Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 8Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 9Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 10Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 11Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 12Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Drew Crawford Announces Launch of PBM365 Media 2
... Test builds on company,s suite of tests to ... Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing ... new diagnostic assay designed to help physicians better ... infections. The company will introduce the Pneumococcal ...
... of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI ... Given With Standard Platelet TherapyKENILWORTH, N.J., March 12 ... ) Phase II trial of SCH 530348, a novel ... The Lancet and demonstrated that the investigational ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... planned ECCE with peristaltic pump with ... suction, reflux possible with multi-function footswitch ... all critical functions. You can also ... actual vacuum level indicated by Bar ...
Medicine Products: